Matinas BioPharma Holdings, Inc. (MTNB) Return on equity 2016–2024
Matinas BioPharma Holdings, Inc. (MTNB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-126.0%FY2024 · since FY2016: -125.1% → -126.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -126.0% | -63.4 pp |
| FY2023 | -62.6% | -22.6 pp |
| FY2022 | -40.0% | -3.5 pp |
| FY2021 | -36.5% | +31.4 pp |
| FY2020 | -67.9% | +39.7 pp |
| FY2019 | -107.6% | +24.2 pp |
| FY2018 | -131.8% | +84.8 pp |
| FY2017 | -216.6% | -91.5 pp |
| FY2016 | -125.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice